Salipro Biotech and DyNAbind enter collaboration agreement
Stockholm, Sweden / Dresden, Germany, 09 November 2020 – Salipro Biotech AB and DyNAbind GmbH are teaming up to tackle drug discovery against challenging membrane protein targets! By bringing together Salipro’s proprietary membrane stabilizing platform technology with DyNAbind’s proprietary DNA-Encoded Library (DEL) technologies, the teams aim to accelerate the development of novel drugs for these contemporary targets. Jens Frauenfeld, co-founder and CEO of Salipro Biotech AB: “We are excited to develop novel hits for challenging drug targets such as GPCR and Ion Channels with DyNAbind.